Pharmacia & Upjohn submit pramipexole NDA for Parkinson's disease monotherapy.
Executive Summary
PHARMACIA & UPJOHN PRAMIPEXOLE PARKINSON's THERAPY NDA SUBMITTED Dec. 28. Pramipexole, which was discovered by Boehringer Ingelheim and co-developed by Upjohn, is a dopamine agonist. The company claims that the compound shows preferential D3 agonist activity compared to a mixed agonist/antagonist profile of other dopamine agents, that it is a full dopamine agonist and that it binds more selectively to dopamine receptors.